Table 4.
Factors associated with switching from warfarin to a DOAC during the pandemic
| Univariable logistic regression | Mixed effects logistic regression* | ||||
| OR | 95% CI | OR | 95% CI | ||
| Age (years) | Under 65 | Ref | Ref | ||
| 65–74 | 2.05 | 1.93 to 2.17 | 1.50 | 1.41 to 1.60 | |
| 75 and over | 2.87 | 2.72 to 3.03 | 1.89 | 1.78 to 2.01 | |
| Index of multiple deprivation | Quintile 5 (least deprived) | Ref | Ref | ||
| Quintile 4 | 1.13 | 1.07 to 1.19 | 1.07 | 1.01 to 1.13 | |
| Quintile 3 | 1.21 | 1.15 to 1.27 | 1.07 | 1.02 to 1.13 | |
| Quintile 2 | 1.20 | 1.14 to 1.26 | 1.05 | 1.00 to 1.11 | |
| Quintile 1 (most deprived) | 1.20 | 1.14 to 1.27 | 1.03 | 0.97 to 1.08 | |
| Care home | No | Ref | Ref | ||
| Yes | 1.47 | 1.29 to 1.68 | 1.32 | 1.15 to 1.51 | |
| Atrial fibrillation | No | Ref | Ref | ||
| Yes | 2.49 | 2.39 to 2.58 | 1.95 | 1.87 to 2.03 | |
| eGFR | ≥60 | Ref | Ref | ||
| Not measured | 0.38 | 0.36 to 0.40 | 0.40 | 0.38 to 0.42 | |
| 30–59 | 1.12 | 1.08 to 1.17 | 0.92 | 0.88 to 0.96 | |
| <30 | 0.63 | 0.57 to 0.70 | 0.51 | 0.46 to 0.57 | |
| Other RFT | 2.20 | 2.10 to 2.30 | 2.11 | 2.02 to 2.21 | |
| Number of recent INR tests | 0 | Ref | Ref | ||
| 1–3 | 1.50 | 1.42 to 1.58 | 1.35 | 1.28 to 1.42 | |
| 4–6 | 1.96 | 1.85 to 2.06 | 1.75 | 1.66 to 1.85 | |
| 7+ | 1.99 | 1.88 to 2.11 | 1.88 | 1.77 to 1.99 | |
| Length of warfarin prescription (years) | <2 | Ref | Ref | ||
| 2–≤6 | 1.69 | 1.54 to 1.85 | 1.26 | 1.14 to 1.38 | |
| 6–<8 | 1.89 | 1.72 to 2.07 | 1.31 | 1.19 to 1.44 | |
| ≥8 | 1.58 | 1.44 to 1.73 | 1.14 | 1.04 to 1.26 | |
| Previous DOAC prescription | No | Ref | Ref | ||
| Yes | 0.65 | 0.60 to 0.70 | 0.65 | 0.60 to 0.70 | |
| DOAC contraindication | No | Ref | Ref | ||
| Yes | 0.41 | 0.30 to 0.58 | 0.37 | 0.26 to 0.52 | |
Patient counts are reported in online supplemental table S3.
*Adjusted for the variables in the table STP membership as a random effect.
DOAC, direct-acting oral anticoagulant.